What Is 2-C-methyl-D-erythrose 4-phosphate

Content on WhatAnswers is provided "as is" for informational purposes. While we strive for accuracy, we make no guarantees. Content is AI-assisted and should not be used as professional advice.

Last updated: April 15, 2026

Quick Answer: 2-C-methyl-D-erythrose 4-phosphate (MEP) is a key intermediate in the non-mevalonate pathway for isoprenoid biosynthesis, discovered in the 1990s. It is synthesized from 1-deoxy-D-xylulose 5-phosphate and plays a critical role in producing essential compounds in bacteria, algae, and plants.

Key Facts

2-C-methyl-D-erythrose 4-phosphate is an intermediate in the MEP pathway, identified in the 1990s.
It is synthesized from 1-deoxy-D-xylulose 5-phosphate (DXP) via the enzyme DXP reductoisomerase.
The MEP pathway occurs in plastids of plants and most bacteria, unlike the mevalonate pathway in animals.
Approximately 80% of living organisms use the MEP pathway for isoprenoid synthesis.
Antibiotics like fosmidomycin inhibit DXP reductoisomerase, blocking MEP formation and killing pathogens.

Overview

2-C-methyl-D-erythrose 4-phosphate (MEP) is a four-carbon sugar phosphate that serves as a metabolic intermediate in the biosynthesis of isoprenoids, a diverse class of natural compounds essential for life. It is formed early in the non-mevalonate pathway, also known as the MEP pathway or DOXP pathway, which operates in most bacteria, cyanobacteria, algae, and plant chloroplasts.

This pathway is distinct from the mevalonate pathway used by animals and archaea, making MEP a target for antimicrobial drug development. The compound plays a pivotal role in synthesizing isopentenyl diphosphate (IPP) and dimethylallyl diphosphate (DMAPP), the building blocks for isoprenoids such as carotenoids, sterols, and essential oils.

Chemical formula: C₅H₁₁O₈P, with a molecular weight of 242.11 g/mol, reflecting its phosphorylated sugar structure.
It is derived from 1-deoxy-D-xylulose 5-phosphate (DXP) through a NADPH-dependent rearrangement catalyzed by DXP reductoisomerase.
The conversion of DXP to MEP is the first committed step in the MEP pathway, making it a regulatory checkpoint.
MEP is unstable and not typically isolated; its presence is inferred through enzyme assays and isotopic labeling studies from the 1990s.
It is exclusively found in organisms lacking the mevalonate pathway, including Plasmodium falciparum, the malaria parasite, which relies on this route.

How It Works

The function of 2-C-methyl-D-erythrose 4-phosphate lies in its role as a precursor in a seven-step enzymatic cascade leading to IPP and DMAPP. Each transformation is catalyzed by specific enzymes, many of which are absent in humans, offering therapeutic potential.

DXP reductoisomerase: Converts DXP to MEP using NADPH as a cofactor; this enzyme is inhibited by fosmidomycin, an antibiotic in clinical trials.
MEP synthase: Though often used interchangeably, MEP synthase refers to the enzyme producing DXP, not MEP—DXR (IspC) produces MEP.
ATP-dependent activation: MEP is phosphorylated to 2-C-methyl-D-erythritol 2,4-cyclodiphosphate (MEcPP) in later steps requiring ATP and CTP.
IPP yield: Each molecule of MEP ultimately contributes to the formation of one molecule of IPP, the universal isoprenoid precursor.
Localization: In plants, MEP synthesis occurs in chloroplast stroma, linking photosynthesis to terpenoid production.
Evolutionary significance: The MEP pathway is present in over 80% of prokaryotes, indicating its ancient origin and metabolic efficiency.

Comparison at a Glance

Below is a comparison of the MEP pathway and the mevalonate pathway, highlighting key differences in distribution, intermediates, and biomedical relevance:

Feature	MEP Pathway	Mevalonate Pathway
Organisms	Bacteria, plants, algae, Plasmodium	Animals, fungi, archaea
Initial substrate	Pyruvate + G3P	Acetyl-CoA
Key intermediate	2-C-methyl-D-erythrose 4-phosphate	HMG-CoA
First committed step	DXP → MEP by DXP reductoisomerase	Acetyl-CoA → HMG-CoA
Drug targets	Fosmidomycin (DXR inhibitor)	Statins (HMG-CoA reductase inhibitors)

The MEP pathway’s absence in humans makes it an ideal target for antibiotics and antimalarials. Fosmidomycin, which blocks MEP synthesis, has shown efficacy in reducing Plasmodium load in clinical trials, though with variable patient response.

Why It Matters

Understanding 2-C-methyl-D-erythrose 4-phosphate is crucial for advancing antimicrobial therapies, improving crop resilience, and developing sustainable bioproducts. Its unique distribution across pathogens and plants offers a biochemical 'Achilles heel' for targeted interventions.

Antibiotic development: Inhibiting MEP synthesis with fosmidomycin selectively kills bacteria without harming human cells.
Antimalarial potential:Plasmodium depends on the MEP pathway, making DXR a validated drug target in malaria treatment.
Herbicide design: Disrupting MEP in weeds can lead to selective herbicides that spare crops with alternative pathways.
Metabolic engineering: Engineered E. coli strains use the MEP pathway to produce artemisinin precursors at industrial scale.
Carbon fixation link: In photosynthetic organisms, MEP production is tied to Calvin cycle intermediates, linking primary and secondary metabolism.
Evolutionary insight: The pathway’s conservation suggests horizontal gene transfer played a role in its spread among prokaryotes.

As research continues, MEP remains a cornerstone in both fundamental biochemistry and applied biotechnology, bridging plant science, medicine, and industrial innovation.